Immunology Department, Weizmann Institute of Science, Rehovot, Israel.
Results Probl Cell Differ. 2020;69:539-557. doi: 10.1007/978-3-030-51849-3_20.
The microbiome field is increasingly raising interest among scientists, clinicians, biopharmaceutical entities, and the general public. Technological advances from the past two decades have enabled the rapid expansion of our ability to characterize the human microbiome in depth, highlighting its previously underappreciated role in contributing to multifactorial diseases including those with unknown etiology. Consequently, there is growing evidence that the microbiome could be utilized in medical diagnosis and patient stratification. Moreover, multiple gut microbes and their metabolic products may be bioactive, thereby serving as future potential microbiome-targeting or -associated therapeutics. Such therapies could include new generation probiotics, prebiotics, fecal microbiota transplantations, postbiotics, and dietary modulators. However, microbiome research has also been associated with significant limitations, technical and conceptual challenges, and, at times, "over-hyped" expectations that microbiome research will produce quick solutions to chronic and mechanistically complex human disorders. Herein, we summarize these challenges and also discuss some of the realistic promises associated with microbiome research and its applicability into clinical application.
微生物组领域越来越引起科学家、临床医生、生物制药实体和公众的兴趣。过去二十年的技术进步使我们深入描述人类微生物组的能力迅速扩大,突出了其在导致多因素疾病(包括病因不明的疾病)方面以前未被充分认识的作用。因此,越来越多的证据表明,微生物组可用于医学诊断和患者分层。此外,多种肠道微生物及其代谢产物可能具有生物活性,从而成为未来潜在的微生物组靶向或相关治疗方法。此类疗法可能包括新一代益生菌、益生元、粪便微生物移植、后生元和饮食调节剂。然而,微生物组研究也存在着显著的局限性、技术和概念上的挑战,有时还存在着“过度炒作”的期望,即微生物组研究将为慢性和机制复杂的人类疾病提供快速解决方案。本文总结了这些挑战,并讨论了与微生物组研究及其在临床应用中的适用性相关的一些现实承诺。